Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

VIC 1911

Next Previous
Drug Profile

VIC 1911

Alternative Names: TAS-119; TAS-2104; VIC-1911

Latest Information Update: 01 Aug 2024

Price :
$50 *
Note:
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Taiho Pharmaceutical
  • Developer Taiho Pharmaceutical; VITRAC Therapeutics
  • Class Antineoplastics; Small molecules
  • Mechanism of Action Aurora kinase A inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Phase I/II Graft-versus-host disease
  • Phase I Non-small cell lung cancer
  • Clinical Phase Unknown Liver cancer
  • Preclinical Triple negative breast cancer
  • Discontinued Solid tumours

Most Recent Events

  • 25 Jul 2024 Clinical trials in Liver cancer (Late-stage disease, Combination therapy) in China (PO) (NCT06519721)
  • 31 May 2024 Adverse events and efficacy data from phase I trial in Non-small cell lung cancer presented at the 60th Annual Meeting of the American Society of Clinical Oncology (ASCO-2024)
  • 09 Dec 2023 Pharmacodynamic and safety data from phase I/II trial in Graft vs host disease presented at the 65th American Society of Hematology Annual Meeting and Exposition (ASH-Hem-2023)

You need to be a logged in or subscribed to view this content

Request demo (opens in a new window)
If your organization or you do not have a subscription, try one of the following: If your organization has a subscription, there are several access options, even while working remotely:
  • Working within your organization’s network
  • with username/password or try to via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days
Back to top